Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Influence of Age on Efficacy and Safety of Spironolactone in Heart Failure.

Vardeny O, Claggett B, Vaduganathan M, Beldhuis I, Rouleau J, O'Meara E, Anand IS, Shah SJ, Sweitzer NK, Fang JC, Desai AS, Lewis EF, Pitt B, Pfeffer MA, Solomon SD; TOPCAT Investigators.

JACC Heart Fail. 2019 Dec;7(12):1022-1028. doi: 10.1016/j.jchf.2019.08.019.

PMID:
31779923
2.

Effects of Sacubitril-Valsartan, versus Valsartan, in Women Compared to Men with Heart Failure and Preserved Ejection Fraction: Insights from PARAGON-HF.

McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J, Lefkowitz MP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Rizkala AR, Sabarwal SV, Shah AM, Shah SJ, Shi VC, van Veldhuisen DJ, Zannad F, Zile MR, Cikes M, Goncalvesova E, Katova T, Kosztin A, Lelonek M, Sweitzer NK, Vardeny O, Claggett B, Jhund PS, Solomon SD.

Circulation. 2019 Nov 17. doi: 10.1161/CIRCULATIONAHA.119.044491. [Epub ahead of print]

PMID:
31736337
3.

Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.

Mohanty AF, Levitan EB, Dodson JA, Vardeny O, King JB, LaFleur J, He T, Patterson OV, Alba PR, Russo PA, Choi ME, Bress AP.

Circ Heart Fail. 2019 Nov;12(11):e005691. doi: 10.1161/CIRCHEARTFAILURE.118.005691. Epub 2019 Nov 13.

PMID:
31718321
4.

The Sweet Spot: Heart Failure Prevention with SGLT2 Inhibitors.

Vardeny O.

Am J Med. 2019 Sep 5. pii: S0002-9343(19)30706-5. doi: 10.1016/j.amjmed.2019.08.013. [Epub ahead of print] Review.

PMID:
31494110
5.

Interactions Between Influenza and Heart Failure Hospitalizations-Diagnostic and Pathogenetic Issues-Reply.

Kytömaa S, Hegde S, Vardeny O.

JAMA Cardiol. 2019 Jul 10. doi: 10.1001/jamacardio.2019.2220. [Epub ahead of print] No abstract available.

PMID:
31290939
6.

Association of Influenza-like Illness Activity With Hospitalizations for Heart Failure: The Atherosclerosis Risk in Communities Study.

Kytömaa S, Hegde S, Claggett B, Udell JA, Rosamond W, Temte J, Nichol K, Wright JD, Solomon SD, Vardeny O.

JAMA Cardiol. 2019 Apr 1;4(4):363-369. doi: 10.1001/jamacardio.2019.0549.

PMID:
30916717
7.

Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.

Vardeny O, Hernandez AF, Cohen LW, Franklin A, Baqai M, Palmer S, Bierer BE, Cobb N.

Clin Trials. 2019 Jun;16(3):290-296. doi: 10.1177/1740774519832911. Epub 2019 Mar 13.

PMID:
30866676
8.

Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials?

Vaduganathan M, Tahhan AS, Alrohaibani A, Greene SJ, Fonarow GC, Vardeny O, Lindenfeld J, Jessup M, Fiuzat M, O'Connor CM, Butler J.

JACC Heart Fail. 2019 Mar;7(3):267-271. doi: 10.1016/j.jchf.2018.12.016. Review. No abstract available.

PMID:
30819383
9.

Tolvaptan for Volume Management in Heart Failure.

Gunderson EG, Lillyblad MP, Fine M, Vardeny O, Berei TJ.

Pharmacotherapy. 2019 Apr;39(4):473-485. doi: 10.1002/phar.2239. Epub 2019 Apr 1. Review.

PMID:
30802995
10.

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.

Vardeny O, Claggett B, Kachadourian J, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD.

Eur J Heart Fail. 2019 Mar;21(3):337-341. doi: 10.1002/ejhf.1402. Epub 2019 Feb 11.

11.

Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists.

Vardeny O, Vaduganathan M.

JACC Heart Fail. 2019 Feb;7(2):169-172. doi: 10.1016/j.jchf.2018.11.013. Review.

PMID:
30704605
12.

Influenza and Heart Failure: A Catchy Comorbid Combination.

Vardeny O, Solomon SD.

JACC Heart Fail. 2019 Feb;7(2):118-120. doi: 10.1016/j.jchf.2018.11.008. Epub 2019 Jan 2. No abstract available.

PMID:
30611719
13.

Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure.

Bhatt AS, Liang L, DeVore AD, Fonarow GC, Solomon SD, Vardeny O, Yancy CW, Mentz RJ, Khariton Y, Chan PS, Matsouaka R, Lytle BL, Piña IL, Hernandez AF.

JACC Heart Fail. 2018 Oct;6(10):844-855. doi: 10.1016/j.jchf.2018.04.012. Epub 2018 Aug 8.

14.

High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial.

Vardeny O, Udell JA, Joseph J, Farkouh ME, Hernandez AF, McGeer AJ, Talbot HK, Bhatt DL, Cannon CP, Goodman SG, Anand I, DeMets DL, Temte J, Wittes J, Nichol K, Yancy CW, Gaziano JM, Cooper LS, Kim K, Solomon SD.

Am Heart J. 2018 Aug;202:97-103. doi: 10.1016/j.ahj.2018.05.007. Epub 2018 May 23.

15.

When the VEST Does Not Fit: Representations of Trial Results Deviating From Rigorous Data Interpretation.

Allen LA, Adler ED, Bayés-Genis A, Brisco-Bacik MA, Chirinos JA, Claggett B, Cook JL, Fang JC, Gustafsson F, Ho CY, Kapur NK, Klewer SE, Kociol RD, Lanfear DE, Vardeny O, Sweitzer NK.

Circ Heart Fail. 2018 Apr;11(4):e005116. doi: 10.1161/CIRCHEARTFAILURE.118.005116. No abstract available.

PMID:
29666074
16.
17.

Guideline-Directed Medical Therapy and Survival Following Hospitalization in Patients with Heart Failure.

Tran RH, Aldemerdash A, Chang P, Sueta CA, Kaufman B, Asafu-Adjei J, Vardeny O, Daubert E, Alburikan KA, Kucharska-Newton AM, Stearns SC, Rodgers JE.

Pharmacotherapy. 2018 Apr;38(4):406-416. doi: 10.1002/phar.2091. Epub 2018 Mar 22.

18.

Association of Resting Heart Rate and Temporal Changes in Heart Rate With Outcomes in Participants of the Atherosclerosis Risk in Communities Study.

Vazir A, Claggett B, Cheng S, Skali H, Shah A, Agulair D, Ballantyne CM, Vardeny O, Solomon SD.

JAMA Cardiol. 2018 Mar 1;3(3):200-206. doi: 10.1001/jamacardio.2017.4974.

19.

PARADIGM-HF Trial: Secondary Analyses Address Unanswered Questions.

Smith KR, Hsu CC, Berei TJ, Aldemerdash A, Hollis IB, Vardeny O, Rodgers JE.

Pharmacotherapy. 2018 Feb;38(2):284-298. doi: 10.1002/phar.2075. Review.

PMID:
29265423
20.

Spironolactone and Resistant Hypertension in Heart Failure With Preserved Ejection Fraction.

Rossignol P, Claggett BL, Liu J, Vardeny O, Pitt B, Zannad F, Solomon S.

Am J Hypertens. 2018 Mar 10;31(4):407-414. doi: 10.1093/ajh/hpx210.

21.

An NPPB Promoter Polymorphism Associated With Elevated N-Terminal pro-B-Type Natriuretic Peptide and Lower Blood Pressure, Hypertension, and Mortality.

Seidelmann SB, Vardeny O, Claggett B, Yu B, Shah AM, Ballantyne CM, Selvin E, MacRae CA, Boerwinkle E, Solomon SD.

J Am Heart Assoc. 2017 Mar 24;6(4). pii: e005257. doi: 10.1161/JAHA.116.005257.

22.

Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia.

Rossignol P, Girerd N, Bakris G, Vardeny O, Claggett B, McMurray JJV, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Spanyers S, Vincent J, Fay R, Lamiral Z, Solomon SD, Zannad F, Pitt B.

Eur J Heart Fail. 2017 Jun;19(6):792-799. doi: 10.1002/ejhf.688. Epub 2016 Nov 20.

23.

Influenza vaccination: a one-shot deal to reduce cardiovascular events.

Vardeny O, Solomon SD.

Eur Heart J. 2017 Feb 1;38(5):334-337. doi: 10.1093/eurheartj/ehw560. No abstract available.

PMID:
27856498
24.

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.

Desai AS, Vardeny O, Claggett B, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Zile MR, Lefkowitz M, Shi V, Solomon SD.

JAMA Cardiol. 2017 Jan 1;2(1):79-85. doi: 10.1001/jamacardio.2016.4733.

PMID:
27842179
25.

Pharmacogenomics of heart failure: a systematic review.

Mottet F, Vardeny O, de Denus S.

Pharmacogenomics. 2016 Nov;17(16):1817-1858. Epub 2016 Nov 4. Review.

PMID:
27813451
26.

Association of Weight and Body Composition on Cardiac Structure and Function in the ARIC Study (Atherosclerosis Risk in Communities).

Bello NA, Cheng S, Claggett B, Shah AM, Ndumele CE, Roca GQ, Santos AB, Gupta D, Vardeny O, Aguilar D, Folsom AR, Butler KR, Kitzman DW, Coresh J, Solomon SD.

Circ Heart Fail. 2016 Aug;9(8). pii: e002978. doi: 10.1161/CIRCHEARTFAILURE.115.002978.

27.

Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial.

Vardeny O, Claggett B, Packer M, Zile MR, Rouleau J, Swedberg K, Teerlink JR, Desai AS, Lefkowitz M, Shi V, McMurray JJ, Solomon SD; Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Investigators.

Eur J Heart Fail. 2016 Oct;18(10):1228-1234. doi: 10.1002/ejhf.580. Epub 2016 Jun 10.

28.

High-dose influenza vaccine in older adults.

Wang JM, Vardeny O, Zorek JA.

J Am Pharm Assoc (2003). 2016 Jan;56(1):95-7. doi: 10.1016/j.japh.2015.12.001. No abstract available.

PMID:
26802928
29.

Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF Trial.

Vardeny O, Claggett B, Udell JA, Packer M, Zile M, Rouleau J, Swedberg K, Desai AS, Lefkowitz M, Shi V, McMurray JJV, Solomon SD; PARADIGM-HF Investigators.

JACC Heart Fail. 2016 Feb;4(2):152-158. doi: 10.1016/j.jchf.2015.10.012. Epub 2015 Dec 30.

30.

Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study.

Gori M, Gupta DK, Claggett B, Selvin E, Folsom AR, Matsushita K, Bello NA, Cheng S, Shah A, Skali H, Vardeny O, Ni H, Ballantyne CM, Astor BC, Klein BE, Aguilar D, Solomon SD.

Diabetes Care. 2016 May;39(5):677-85. doi: 10.2337/dc15-1760. Epub 2016 Jan 6.

31.

Response to Letter Regarding Article, “Cardiac Structure and Function Across the Glycemic Spectrum in Elderly Men and Women Free of Prevalent Heart Disease: The Atherosclerosis Risk In the Community Study”.

Skali H, Shah A, Gupta, Cheng S, Claggett B, Liu J, Bello N, Aguilar D, Vardeny O, Matsushita K, Selvin E, Solomon S.

Circ Heart Fail. 2015 Sep;8(5):1010. No abstract available.

PMID:
26625500
32.

The Role of Neprilysin Inhibitors in Cardiovascular Disease.

Mills J, Vardeny O.

Curr Heart Fail Rep. 2015 Dec;12(6):389-94. doi: 10.1007/s11897-015-0270-8.

PMID:
26466607
33.

Does influenza vaccination influence cardiovascular complications?

Udell JA, Farkouh ME, Solomon SD, Vardeny O.

Expert Rev Cardiovasc Ther. 2015 Jun;13(6):593-6. doi: 10.1586/14779072.2015.1044439. Epub 2015 May 14.

PMID:
25971953
34.

Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk In the Community study.

Skali H, Shah A, Gupta DK, Cheng S, Claggett B, Liu J, Bello N, Aguilar D, Vardeny O, Matsushita K, Selvin E, Solomon S.

Circ Heart Fail. 2015 May;8(3):448-54. doi: 10.1161/CIRCHEARTFAILURE.114.001990. Epub 2015 Mar 10.

35.

Angiotensin receptor-neprilysin inhibitors in heart failure: a shifting paradigm.

Vardeny O.

Evid Based Med. 2015 Apr;20(2):61. doi: 10.1136/ebmed-2014-110112. Epub 2015 Feb 6. No abstract available.

PMID:
25659916
36.

Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure.

Vardeny O, Miller R, Solomon SD.

JACC Heart Fail. 2014 Dec;2(6):663-70. doi: 10.1016/j.jchf.2014.09.001. Epub 2014 Oct 8. Review.

37.

Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.

Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators.

Circ Heart Fail. 2014 Jul;7(4):573-9. doi: 10.1161/CIRCHEARTFAILURE.114.001104. Epub 2014 May 8.

PMID:
24812304
38.

Insulin resistance and incident heart failure the ARIC study (Atherosclerosis Risk in Communities).

Vardeny O, Gupta DK, Claggett B, Burke S, Shah A, Loehr L, Rasmussen-Torvik L, Selvin E, Chang PP, Aguilar D, Solomon SD.

JACC Heart Fail. 2013 Dec;1(6):531-6.

39.

Lack of persistence of influenza vaccine antibody titers in patients with heart failure.

Albrecht CM, Sweitzer NK, Johnson MR, Vardeny O.

J Card Fail. 2014 Feb;20(2):105-9. doi: 10.1016/j.cardfail.2013.12.008. Epub 2013 Dec 19.

40.

Nonprescription medication use in patients with heart failure: assessment methods, utilization patterns, and discrepancies with medical records.

Mattila M, Boehm L, Burke S, Kashyap A, Holschbach L, Miller T, Vardeny O.

J Card Fail. 2013 Dec;19(12):811-5. doi: 10.1016/j.cardfail.2013.10.009. Epub 2013 Oct 30.

PMID:
24184371
41.

Race influences the safety and efficacy of spironolactone in severe heart failure.

Vardeny O, Cavallari LH, Claggett B, Desai AS, Anand I, Rossignol P, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators.

Circ Heart Fail. 2013 Sep 1;6(5):970-6. doi: 10.1161/CIRCHEARTFAILURE.113.000530. Epub 2013 Aug 12.

PMID:
23940307
42.

First-in-class angiotensin receptor neprilysin inhibitor in heart failure.

Vardeny O, Tacheny T, Solomon SD.

Clin Pharmacol Ther. 2013 Oct;94(4):445-8. doi: 10.1038/clpt.2013.146. Epub 2013 Jul 19.

PMID:
23872864
43.

Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network.

Milfred-Laforest SK, Chow SL, Didomenico RJ, Dracup K, Ensor CR, Gattis-Stough W, Heywood JT, Lindenfeld J, Page RL 2nd, Patterson JH, Vardeny O, Massie BM.

J Card Fail. 2013 May;19(5):354-69. doi: 10.1016/j.cardfail.2013.02.002. Epub 2013 Apr 6.

PMID:
23663818
44.

Clinical pharmacy services in heart failure: an opinion paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network.

Milfred-LaForest SK, Chow SL, DiDomenico RJ, Dracup K, Ensor CR, Gattis-Stough W, Heywood JT, Lindenfeld J, Page RL 2nd, Patterson JH, Vardeny O, Massie BM.

Pharmacotherapy. 2013 May;33(5):529-48. doi: 10.1002/phar.1295.

PMID:
23649813
45.

Key articles and guidelines in the primary prevention of ischemic stroke.

Baker WL, Marrs JC, Davis LE, Nutescu EA, Rowe AS, Ryan M, Splinter MY, Vardeny O, Fagan SC.

Pharmacotherapy. 2013 Jun;33(6):e101-14. doi: 10.1002/phar.1255. Epub 2013 Feb 11.

PMID:
23401140
46.

Key articles and guidelines in the acute management and secondary prevention of ischemic stroke.

Baker WL, Marrs JC, Davis LE, Nutescu EA, Rowe AS, Ryan M, Splinter MY, Vardeny O, Fagan SC.

Pharmacotherapy. 2013 Jun;33(6):e115-42. doi: 10.1002/phar.1252. Epub 2013 Feb 11.

PMID:
23401103
47.

Double dose vs. standard dose influenza vaccination in patients with heart failure: a pilot study.

Van Ermen A, Hermanson MP, Moran JM, Sweitzer NK, Johnson MR, Vardeny O.

Eur J Heart Fail. 2013 May;15(5):560-4. doi: 10.1093/eurjhf/hfs207. Epub 2013 Jan 4.

48.

Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study).

Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD; RALES Investigators.

J Am Coll Cardiol. 2012 Nov 13;60(20):2082-9. doi: 10.1016/j.jacc.2012.07.048. Epub 2012 Oct 17.

49.

β-AR polymorphisms and glycemic and lipid parameters in hypertensive individuals receiving carvedilol or metoprolol.

Vardeny O, Nicholas G, Andrei A, Buhr KA, Hermanson MP, Moran JJ, Detry MA, Stein JH.

Am J Hypertens. 2012 Aug;25(8):920-6. doi: 10.1038/ajh.2012.54. Epub 2012 May 31.

50.

Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression.

Vardeny O, Pouleur AC, Takeuchi M, Appelbaum E, Verma A, Prescott M, Smith B, Dahlof B, Solomon SD; ALLAY Investigators.

J Renin Angiotensin Aldosterone Syst. 2012 Jun;13(2):265-72. doi: 10.1177/1470320312437893. Epub 2012 Mar 13.

PMID:
22415888

Supplemental Content

Loading ...
Support Center